Second, the off-label adoption pattern that the longevity reframing will inevitably accelerate is going to produce the next wave of monitoring, dosing, and selection problems, patients without obesity or diabetes do not have the diagnostic anchors (BMI, A1c, insulin resistance markers) that frame the on-label conversation, and the clinical infrastructure for managing GLP-1 therapy in metabolically healthy users is, charitably described, thin
ChREBP was down-regulated in patients with NAFLD ( n = 22) compared to healthy controls ( n = 10), and instead, SREBP1c was reported to be one of the predominant regulators of DNL in NAFLD, upregulating genes coding for ACC1 and FAS [53]
So if you would lose 4 kg from dieting, Alli might help you lose 6 kg
GLP-1 medications, on the other hand, offer a science-backed, non-invasive alternative that has transformed weight management for many patients
10.1016/S0140-6736(16)31679-8 54
So, body recompositions are something you have to be a little more patient with when it comes to seeing results